Drugs / ATL001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03997474 | Aug 2019 → Sep 2024 | melanoma | Achilles Therapeutics UK Limited | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04032847 | Jul 2019 → Sep 2024 | non-small cell lung carcinoma | Achilles Therapeutics UK Limited | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATL001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04032847 ↗ |
| Modality | Cell therapy | “autologous clonal neoantigen reactive T cells (cNeT)” NCT03997474 ↗ |
| Route | Intravenous | “administered intravenously” NCT03997474 ↗ |